Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by aldo451on Dec 29, 2018 4:28pm
180 Views
Post# 29168393

RE:Here's a rumour and/ or possibility...

RE:Here's a rumour and/ or possibility... Merci Friponeau,

for sharing, interesting read indeed.

On a different note, can you tell me how to access the FB group so that I can request admission. I have tried “Prometic shareholder private discussion board” but no success.
 
Thanks in advance

Friponeau wrote:
From a boardmember on FB.  

"Well, well, here it is this rumor very valid. Have a good weekend!!!
 
Here's what I learned ...
 
Aquinox is a Vancouver-based pharma company listed on the Nasdaq (AQXP). She has a $ 50 million market cap while she has $ 85 million in cash. Last June she declared in a phase 3 of a product to treat bladder fibrosis. She has had to stop all her work and is now looking for a project to boost her cash and Nasdaq registration. Major merchant banks would be soliciting for them and the file would have been presented to Prometic last November.
 
 It would be an interesting partnership for Prometic. A merger-acquisition would allow by exchange of shares to obtain cash covering 1 year of operation in addition to an immediate registration Nasdaq. Obviously Aquinox will have its requirements and it must be strongly courted by other players. Our new CEO, Simon Best and Bruce Wendel, our Chief Business Development Officer, have a great opportunity to showcase their talents. Bruce has been in office since April, so it's time to report his work to shareholders.
 
 Could someone relay on Stockhouse and ask Fred Dumais about this matter?"


Bullboard Posts